Todd B. Sherer, PhD

Michael J Fox Foundation 
"Todd Sherer"
Mean distance: 17.21 (cluster 32)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chahine LM, Merchant K, Siderowf A, et al. (2023) Proposal for a Biologic Staging System of Parkinson's Disease. Journal of Parkinson's Disease
Merchant KM, Simuni T, Fedler J, et al. (2023) LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. Npj Parkinson's Disease. 9: 30
Frasier M, Fiske BK, Sherer TB. (2022) Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience. 14: 1064057
Schiess N, Cataldi R, Okun MS, et al. (2022) Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. Jama Neurology
Espay AJ, Kalia LV, Gan-Or Z, et al. (2020) Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology
Dorsey E, Sherer T, Okun M, et al. (2020) The Rise of Parkinson's Disease American Scientist. 108: 176
Espay AJ, Vizcarra JA, Marsili L, et al. (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337
Prakash N, Caspell-Garcia C, Coffey C, et al. (2019) Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism & Related Disorders
Dorsey ER, Sherer T, Okun MS, et al. (2018) The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson's Disease. 8: S3-S8
Marek K, Chowdhury S, Siderowf A, et al. (2018) The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology. 5: 1460-1477
See more...